The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2021 | MGC018 in patients with advanced solid tumors
Eugene Shenderov, MD, PhD, Johns Hopkins Medicine, Baltimore, MD, gives an update on the Phase I cohort expansion of the clinical trial (NCT03729596) investigating the use of MGC018, an anti-B7-H3 antibody-drug conjugate containing duocarmycin, to treat patients with advanced solid tumors. The preliminary data focuses on patients with non-small cell lung cancer and metastatic castration-resistant prostate cancer. MGC018 shows strong efficacy, with over half of evaluable patients showing a decrease of more than 50% of prostate-specific antigen (PSA) and several patients showing promising radiographic responses. Treatment-associated adverse events were common (88% of patients) and the tolerability of the drug needs to be improved. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.
Disclosures
Dr Shenderov’s disclosures are as follows: founder and CEO of LifeImmune, Inc; has received clinical trial institutional research funding from MacroGenics, and has served as a consultant for Firstthought.io and Guidepoint Global.
